following an abbreviated submission:
apalutamide (Erleada®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
Apalutamide offers an additional treatment choice in the therapeutic class of selective androgen receptor inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice637KB (PDF)
Medicine details
- Medicine name:
- apalutamide (Erleada)
- SMC ID:
- SMC2579
- Indication:
In adult men for the treatment of non‑metastatic castration‑resistant prostate cancer (NM‑nmCRPC) who are at high risk of developing metastatic disease
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 July 2023